Stock market today: Asia shares decline as investors await earnings, US elections and economic data
Asian shares mostly declined Thursday as investors grappled with uncertainty ahead of the United States presidential election on Nov. 5.
Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St.
The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its ...
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Access WDUN11h
Stock market today: Wall Street churns as Alphabet jumps, Eli Lilly tumbles
A mixed set of profit reports from giants like Google’s parent company and Eli Lilly has stock indexes basically churning in ...
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...